Australian Particle Therapy Clinical Quality Registry


Australian Particle Therapy Clinical Quality Registry (ASPIRE) is a prospective, observational, longitudinal study of paediatric, adolescent, young adult and rare adult tumour patients from a select group of tumour streams treated with radiation therapy. Comparing the long-term toxicities of photon and proton radiation therapy.

For more about ASPIRE visit: https://www.protontherapy.sahmri.org.au/about-aptcqr/

Primary Sponsor

South Australian Health & Medical Research Institute (Australian Bragg Centre for Proton Therapy and Research)

Collaborating Groups

TROG Cancer Research

Trial Chairperson

A/Prof Hien Le, Royal Adelaide Hospital, SA

Trial Contact

ASPIRE@sahmri.com

Clinical Trial Registration

Related Post

5 December, 2024

Extended follow-up of TROG 99.03 lymphoma trial published

5 December 2024: Study shows huge improvement in progression-free

28 November, 2024

Meet TROG President: A/Prof Puma Sandaresan

28 November 2024: In this Q&A, TROG President A/Prof